Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Limited functional tumor-infiltrating lymphocytes correlate with poor cancer patient prognosis.
• Interleukin-21 (IL-21) shows potential for anti-tumor effects but requires improved delivery and reduced toxicity.

Purpose of the Study:

• To develop an Erbitux-based IL-21 fusion protein (Erb-IL21) with enhanced half-life and tumor-targeting capabilities.
• To evaluate the anti-tumor efficacy and toxicity of Erb-IL21 in vivo.
• To elucidate the mechanism of Erb-IL21-mediated tumor control.

Main Methods:

• Construction and in vivo evaluation of an Erbitux-IL-21 fusion protein (Erb-IL21).
• Assessment of Erb-IL21 toxicity compared to Erb-IL2.
• Analysis of T cell populations (cytotoxic T lymphocytes, CD8+ T cells) within the tumor microenvironment (TME).
• Evaluation of Erb-IL21 in overcoming checkpoint blockade resistance in advanced tumor models.

Main Results:

• Erb-IL21 exhibited significantly lower toxicity compared to Erb-IL2 in vivo.
• Erb-IL21 selectively expanded functional cytotoxic T lymphocytes within the TME, sparing dysfunctional CD8+ T cells.
• The anti-tumor effect of IL-21 was dependent on pre-existing intratumoral CD8+ T cells.
• Erb-IL21 demonstrated efficacy in overcoming resistance to checkpoint blockade in mice with advanced tumors.

Conclusions:

• Erb-IL21 effectively targets IL-21 to tumors, enhancing anti-tumor immunity.
• Erb-IL21 maximizes the potential of checkpoint blockade by expanding tumor-specific CD8+ T cells for effective tumor control.
• This fusion protein represents a promising strategy for improving cancer immunotherapy.